The company scheduled the trial of its obesity drug to begin in January, after Christmas, which is characterized by overeating.
Bio-Light Israeli Life Sciences Investments Ltd. (TASE:BOLT) subsidiary OBEcure Ltd. will begin Phase II human clinical trials of its obesity treatment in the US in January 2007. The trial aims to gather clear statistical data on the drug’s effectiveness. The company has scheduled the trial to begin in January, after Christmas, which is characterized by overeating during holiday season.
The trial is schedule to take three months, after which several more months will pass before the US Food and Drug Administration (FDA) decides whether to allow OBEcure to proceed with its treatment. In other words, the company is unlikely to make an important announcement about its drug before mid-2007, although it will report the trial’s interim results.
Published by Globes [online], Israel business news - www.globes.co.il - on September 4, 2006
© Copyright of Globes Publisher Itonut (1983) Ltd. 2006